OCGN

Company Overview — What Does Ocugen, Inc. Do?

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania. Ocugen, Inc. (OCGN) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Shankar Musunuri and employs approximately 80 people, headquartered in MALVERN , Pennsylvania. With a market capitalization of $587M, OCGN is one of the notable companies in the Healthcare sector.

Ocugen, Inc. (OCGN) Stock Rating — Reduce (April 2026)

As of April 2026, Ocugen, Inc. receives a Reduce rating with a composite score of 28.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.OCGN ranks #2,776 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Ocugen, Inc. ranks #382 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

OCGN Stock Price and 52-Week Range

Ocugen, Inc. (OCGN) currently trades at $1.79. The stock lost $0.08 (4.3%) in the most recent trading session. The 52-week high for OCGN is $2.73, which means the stock is currently trading -34.3% from its annual peak. The 52-week low is $0.53, putting the stock 236.8% above its annual trough. Recent trading volume was 6.5M shares, reflecting moderate market activity.

Is OCGN Overvalued or Undervalued? — Valuation Analysis

Ocugen, Inc. (OCGN) carries a value factor score of 23/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 213.46x, versus the sector average of 2.75x. The price-to-sales ratio is 99.36x, compared to 1.66x for the average Healthcare stock.

At current multiples, Ocugen, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Ocugen, Inc. Profitability — ROE, Margins, and Quality Score

Ocugen, Inc. (OCGN) earns a quality factor score of 11/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -1786.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -145.0% versus the sector average of -33.1%.

On a margin basis, Ocugen, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -1039.1% (sector: -66.1%). Net profit margin stands at -1099.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 53.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

OCGN Debt, Balance Sheet, and Financial Health

Ocugen, Inc. has a debt-to-equity ratio of 1530.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.06x, suggesting adequate working capital coverage. Total debt on the balance sheet is $28M. Cash and equivalents stand at $33M.

OCGN has a beta of 1.34, meaning it is more volatile than the broader market — a $10,000 investment in OCGN would be expected to move 34.0% more than the S&P 500 on any given day. The stability factor score for Ocugen, Inc. is 27/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Ocugen, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Ocugen, Inc. reported revenue of $6M. Net income for the quarter was $-63M. Gross margin was 100.0%. Operating income came in at $-59M.

In FY 2025, Ocugen, Inc. reported revenue of $4M. Net income for the quarter was $-68M. Revenue grew 8.8% year-over-year compared to FY 2024. Operating income came in at $-63M.

In Q3 2025, Ocugen, Inc. reported revenue of $2M. Net income for the quarter was $-20M. Revenue grew 54.2% year-over-year compared to Q3 2024. Operating income came in at $-18M.

In Q2 2025, Ocugen, Inc. reported revenue of $1M. Net income for the quarter was $-15M. Revenue grew 20.3% year-over-year compared to Q2 2024. Operating income came in at $-14M.

Over the past 8 quarters, Ocugen, Inc. has demonstrated a growth trajectory, with revenue expanding from $1M to $6M. Investors analyzing OCGN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

OCGN Dividend Yield and Income Analysis

Ocugen, Inc. (OCGN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

OCGN Momentum and Technical Analysis Profile

Ocugen, Inc. (OCGN) has a momentum factor score of 67/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 22/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 3/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

OCGN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Ocugen, Inc. (OCGN) ranks #382 out of 838 stocks based on the Blank Capital composite score. This places OCGN in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing OCGN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full OCGN vs S&P 500 (SPY) comparison to assess how Ocugen, Inc. stacks up against the broader market across all factor dimensions.

OCGN Next Earnings Date

No upcoming earnings date has been announced for Ocugen, Inc. (OCGN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy OCGN? — Investment Thesis Summary

The quantitative profile for Ocugen, Inc. suggests caution. The quality score of 11/100 flags below-average profitability. The value score of 23/100 indicates premium valuation. Price momentum is positive at 67/100, suggesting the trend favors buyers. High volatility (stability score 27/100) increases portfolio risk.

In summary, Ocugen, Inc. (OCGN) earns a Reduce rating with a composite score of 28.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on OCGN stock.

Related Resources for OCGN Investors

Explore more research and tools: OCGN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare OCGN head-to-head with peers: OCGN vs AZN, OCGN vs SLGL, OCGN vs VMD.